A series of class action lawsuits allege that OptumRx, one of the largest pharmacy benefit managers in the United States, systematically charged health plan members copays that far exceeded the actual retail cost of their generic medications — then pocketed the difference. The scheme, known as a “copay clawback,” works like this: a generic drug might cost $5.00 at a pharmacy’s cash price, but a patient using their insurance pays a $20.00 copayment. OptumRx then claws back the $15.00 difference from the pharmacy, meaning the patient would have been better off not using their insurance at all. Keller Rohrback L.L.P.
Filed a class action against UnitedHealth Group and OptumRx on November 15, 2016, seeking monetary damages on behalf of consumers who overpaid for prescriptions under this billing arrangement. OptumRx is the subject of at least two proposed class-action lawsuits alleging deceptive copay inflation on generic drugs. Making matters worse, contracts between OptumRx and pharmacies specifically prohibited pharmacists from telling customers the true cost of their drugs — even when patients asked directly. These so-called “gag clauses” ensured that most consumers never learned they were overpaying.
Table of Contents
- How Did OptumRx Charge Members Higher Copays Than the Actual Cost of Generic Drugs?
- How Widespread Are Copay Overcharges on Generic Prescriptions?
- FTC Enforcement Actions Against OptumRx and Other Major PBMs
- What Can Affected OptumRx Members Do About Copay Overcharges?
- OptumRx’s Broader History of Regulatory Settlements and Penalties
- How Gag Clauses Kept Patients in the Dark
- What the Ongoing FTC Cases Could Mean for the Future of PBM Pricing
- Frequently Asked Questions
How Did OptumRx Charge Members Higher Copays Than the Actual Cost of Generic Drugs?
The copay clawback scheme exploits a gap between what pharmacies charge for cheap generic drugs and what insurance plans set as fixed copayment amounts. When a generic medication has a retail price of, say, $4.00 or $8.00, but a patient’s plan requires a $15.00 or $20.00 copay for generic drugs, the patient ends up paying more through insurance than they would paying cash out of pocket. The pharmacy benefit manager — in this case OptumRx — collects the full copay from the patient, pays the pharmacy the lower actual cost, and retains the spread. OptumRx controls more than 20% of the pharmacy benefit manager market, making it one of the three dominant PBMs in the country alongside CVS caremark and Express Scripts. That market concentration means millions of Americans filled prescriptions through OptumRx and may have been affected by these pricing practices.
The class action lawsuits argue that OptumRx had a fiduciary obligation to act in the interest of plan members, not to profit from inflated copay structures at their expense. What made this arrangement particularly difficult for consumers to detect was the existence of gag clauses in OptumRx’s contracts with pharmacies. These clauses explicitly barred pharmacists from volunteering that a patient could pay less by skipping their insurance. A pharmacist who watched a customer pay $20.00 for a drug that cost $5.00 cash was contractually forbidden from saying anything. Several states have since passed laws banning these gag clauses, and a federal ban was signed into law in 2018, but the damage during the years these clauses were in effect was significant.
How Widespread Are Copay Overcharges on Generic Prescriptions?
Research from the USC Schaeffer Center, published in 2018, put hard numbers on the scope of the problem. The study found that in 2013, nearly 23% of all filled prescriptions involved a patient copayment that exceeded the insurer’s average reimbursement by more than $2.00. That is roughly one in four prescriptions where the patient overpaid relative to what the drug actually cost the system. The disparity was overwhelmingly concentrated in generic drugs. Overpayments occurred on 28% of generic prescriptions compared to just 6% of brand-name prescriptions.
This makes intuitive sense — generic drugs are cheap, often costing pharmacies just a few dollars, while copay tiers for generics are typically set at $10.00 to $25.00 regardless of the actual drug price. The fixed copay structure, designed for administrative simplicity, becomes a profit engine when the copay consistently exceeds the drug cost. However, it is worth noting that not every generic prescription results in an overpayment. Patients on plans with very low generic copays — $3.00 or $5.00 — are less likely to experience clawbacks. The problem is most acute for patients whose plans set generic copays at $15.00 or higher, and who fill inexpensive generic medications like metformin, lisinopril, or amlodipine that may cost pharmacies under $5.00 for a month’s supply. If you are on a high-deductible plan or a plan with relatively high generic copays, the risk of overpayment is greater.
FTC Enforcement Actions Against OptumRx and Other Major PBMs
Federal regulators have taken increasingly aggressive action against OptumRx and its fellow PBM giants. In September 2024, the Federal Trade Commission sued the three largest PBMs — OptumRx, CVS Caremark, and Express Scripts — for artificially inflating insulin prices through anticompetitive rebating practices. The FTC alleged that these companies used a rebate-driven system that rewarded higher list prices, effectively penalizing manufacturers who tried to lower costs. The FTC’s second interim report on PBM practices went even further, finding that the three largest PBMs had hiked specialty generic drug prices by hundreds to thousands of percent, generating over $7.3 billion in excess revenue compared to the national average drug acquisition cost.
That figure represents money that came directly from patients and health plans while flowing to PBM bottom lines. In February 2026, the FTC secured a landmark settlement with Express Scripts that requires transparency reforms expected to lower patient costs by up to $7 billion over 10 years. The cases against OptumRx and CVS Caremark are still ongoing as of March 2026, and the outcome of those cases could reshape how PBMs set drug prices and copay structures across the industry. If the FTC achieves similar concessions from OptumRx, it could directly benefit the millions of members who have been subject to inflated copay practices.
What Can Affected OptumRx Members Do About Copay Overcharges?
If you believe you have been charged copays exceeding the actual cost of your generic medications through OptumRx, there are several practical steps to consider. First, compare your copay receipts against the cash price of your medications at your pharmacy or on price-comparison tools. If you find that you have been consistently paying $15.00 or $20.00 for drugs that cost $4.00 to $8.00 without insurance, you may have been affected by the clawback practice. Second, ask your pharmacist directly what the cash price of your medication is. Since federal gag clause legislation passed in 2018, pharmacists are now legally permitted to inform you when paying out of pocket would be cheaper than using your insurance.
This is a simple but powerful check — if the cash price is lower than your copay, you can choose to pay cash and avoid the overcharge going forward. The tradeoff is that cash-pay prescriptions typically do not count toward your insurance deductible or out-of-pocket maximum, so patients who are close to meeting their deductible may want to weigh that calculation carefully. Third, monitor the ongoing FTC cases against OptumRx. If a settlement or judgment results in a consumer restitution fund, affected members may be eligible to file claims for past overcharges. Keeping pharmacy receipts and explanation of benefits statements will strengthen any future claim. The Keller Rohrback class action, if it reaches a settlement, may also provide a claims process for affected consumers.
OptumRx’s Broader History of Regulatory Settlements and Penalties
The copay clawback lawsuits are not isolated incidents in OptumRx’s legal history. The company has faced repeated enforcement actions across multiple areas of its business, raising questions about systemic compliance failures. OptumRx paid $15 million to settle allegations that it overcharged Ohio’s workers’ compensation program on prescription drug pricing between 2015 and 2018. Separately, it agreed to pay $5.8 million to resolve similar workers’ compensation pricing violations in Massachusetts. On the federal level, OptumRx paid $20 million to resolve Department of Justice allegations related to opioid prescription violations.
And in a different category entirely, a $1.86 million TCPA settlement in Patterson vs. OptumRx covers consumers who received unauthorized automated calls from the company, with a final hearing scheduled for March 31, 2026. The pattern is worth noting for consumers evaluating the credibility of the copay clawback allegations. A company with a clean regulatory record facing one lawsuit might warrant skepticism about the claims. But OptumRx’s repeated settlements across workers’ compensation overcharging, federal drug law violations, and telemarketing violations suggest a broader pattern of practices that prioritize revenue over compliance. That context does not prove the copay clawback claims are valid, but it makes the allegations considerably more plausible.
How Gag Clauses Kept Patients in the Dark
One of the most troubling elements of the copay clawback scheme was the contractual gag clause that prevented pharmacists from helping their own customers. Pharmacists — the healthcare professionals standing directly in front of the patient — knew that a customer was overpaying but were legally barred from saying so under their contract with OptumRx. Imagine a pharmacist watching a retired patient on a fixed income hand over $20.00 for a bottle of metformin that costs $4.00 cash, unable to speak up without risking their pharmacy’s contract with the PBM.
The bipartisan Know the Lowest Price Act, signed into law in October 2018, banned these gag clauses in Medicare Part D plans, and the Patient Right to Know Drug Prices Act extended the ban to commercial plans. These laws were a direct legislative response to the practices described in the OptumRx lawsuits. But they only apply going forward — they do not compensate patients who overpaid during the years the gag clauses were in effect, which is precisely what the class action lawsuits seek to address.
What the Ongoing FTC Cases Could Mean for the Future of PBM Pricing
The FTC’s active litigation against OptumRx and CVS Caremark, combined with the landmark Express Scripts settlement in February 2026, signals a potential turning point in how pharmacy benefit managers operate. If the FTC secures comparable relief from OptumRx — transparency requirements, limits on spread pricing, restrictions on clawback practices — the structural conditions that enabled copay overcharges could be dismantled industry-wide.
The Express Scripts settlement’s projected $7 billion in patient savings over ten years provides a benchmark for what reform could look like. For OptumRx members, the combination of class action litigation seeking damages for past overcharges and FTC enforcement seeking structural reform for the future represents a two-front effort that could both compensate affected consumers and prevent the practices from continuing. The next 12 to 18 months will be critical as these cases move toward resolution.
Frequently Asked Questions
What is a copay clawback?
A copay clawback occurs when a pharmacy benefit manager like OptumRx charges a patient a copay that exceeds the actual cost of the drug, then recovers the difference from the pharmacy. For example, if a drug costs $5.00 but your copay is $20.00, the PBM claws back the $15.00 difference — meaning you paid $15.00 more than the drug actually cost.
How do I know if I was overcharged by OptumRx?
Compare your copay amounts on generic prescriptions to the cash price at your pharmacy. If your copay consistently exceeds what the drug costs without insurance, you may have been affected. Since 2018, pharmacists are legally allowed to tell you the lowest price, so ask directly.
Is there a current class action settlement I can file a claim for?
As of March 2026, the copay clawback class action lawsuits against OptumRx have not yet reached a settlement with a claims process. The FTC’s case against OptumRx is also still ongoing. However, a separate $1.86 million TCPA settlement in Patterson vs. OptumRx covering unauthorized automated calls has a final hearing scheduled for March 31, 2026 — details are available at optumrxtcpaclassactionsettlement.com.
Are gag clauses still legal?
No. Federal legislation passed in 2018 banned gag clauses that prevented pharmacists from informing patients about lower-cost alternatives. Pharmacists can now tell you if paying cash would be cheaper than using your insurance copay.
Did the FTC take action against OptumRx?
Yes. In September 2024, the FTC sued OptumRx, CVS Caremark, and Express Scripts for artificially inflating drug prices through anticompetitive rebating. The FTC settled with Express Scripts in February 2026, but the cases against OptumRx and CVS Caremark remain active.
Should I stop using my insurance for generic drugs?
It depends on your plan structure. If your generic copay is higher than the cash price, paying cash saves money on that individual prescription. However, cash payments typically do not count toward your deductible or out-of-pocket maximum, so if you are close to meeting either threshold, using insurance may still make strategic sense for the year overall.